GE HealthCare has submitted its MIM KineticID software for FDA review, a step the company says could broaden access to dynamic PET imaging and quantitative kinetic modeling.

The Chicago-based company said the software is designed to support analysis of how radiotracers move through the body over time, a process intended to provide additional quantitative information beyond conventional PET imaging.

PET scans are commonly interpreted using static images and measures such as standardized uptake value, or SUV. While those methods remain widely used, they capture tracer activity at a single point in time. Dynamic PET imaging instead tracks tracer behavior in blood and tissue over a longer period, allowing clinicians and researchers to evaluate uptake and clearance patterns. Kinetic modeling uses those data to quantify biological processes associated with disease.
“Dynamic PET and kinetic modeling are transforming how we understand disease,” said professor Martin Huellner, senior physician and vice director of the Department of Nuclear Medicine at Zurich University Hospital. “Instead of relying on a single moment in time, we can track how a tracer moves through the body and uncover what’s driving what we see.”

According to GE HealthCare, MIM KineticID is intended to provide tools for dynamic PET workflows, including kinetic modeling, parametric imaging, 4D visualization, Patlak analysis and customizable curve fitting. The software is also designed to support whole-body dynamic analysis, automated labeling and comparison of multiple tracers, including FDG and PSMA.

The company said the platform will support DICOM data from PET systems regardless of manufacturer and will integrate with the broader MIM software ecosystem, which includes tools for image fusion, therapy response assessment and multimodality analysis.

In a statement, J Anders, general manager of MIM at GE HealthCare, said demand is growing for imaging tools that provide quantitative information about disease biology and can adapt to new tracers and therapies.

MIM KineticID remains under FDA review and is not currently cleared for sale in the United States or other markets, according to the company.

Molecular Imaging Homepage